GLG News by Niaspan Prescribers for Raising HDL

The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...

The  potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...

More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 

It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.

 Study will be ridiculed.   1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.

Immunomodulation especially with antibodies is difficult.  Proteins are not as easily given and distributed through the body as low molecular weight compounds.  I believe that the first drug to be effective will pave the way for many others

- the next generation of SMIP technology beyond antibody therapy enters clinical trials - the value of efficacy versus safety as compared to TRU-015 and the anti-CD20 antiobodies will be of key importance if it makes sense to broaden this spectrum of second generation anti-CD20s - however, it gives...

The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...